ストックスクリーナーアプリを入手
1.33
2.21%
-0.03
前日終値:
$1.36
開ける：
$1.35
24時間の取引高:
211.27K
Relative Volume:
0.05
時価総額：
$42.77M
収益：
-
当期純損益:
$-16.14M
株価収益率:
-2.463
EPS:
-0.54
ネットキャッシュフロー:
$-3.99M
1週間 パフォーマンス:
+8.13%
1か月 パフォーマンス:
-10.74%
6か月 パフォーマンス:
-70.96%
1年 パフォーマンス:
-78.09%
1日の値動き範囲:
$1.3102
$1.36
1週間の範囲:
$1.22
$1.45
52週間の値動き範囲:
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.325 | 46.01M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.64 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.39 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.86 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
751.27 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
331.36 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Exit strategy if you’re trapped in Telomir Pharmaceuticals Inc.Market Activity Recap & Verified Entry Point Signals - newser.com
Can momentum traders help lift Telomir Pharmaceuticals Inc.Trade Analysis Report & Expert Verified Stock Movement Alerts - newser.com
Price momentum metrics for Telomir Pharmaceuticals Inc. explainedPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Analyzing recovery setups for Telomir Pharmaceuticals Inc. investorsStop Loss & AI Driven Price Forecasts - newser.com
Can you recover from losses in Telomir Pharmaceuticals Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com
Predicting Telomir Pharmaceuticals Inc. trend using moving averages2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
What high frequency data says about Telomir Pharmaceuticals Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser
Telomir Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Backtesting results for Telomir Pharmaceuticals Inc. trading strategiesGap Up & Community Consensus Trade Alerts - Newser
Short interest data insights for Telomir Pharmaceuticals Inc.Weekly Profit Report & Fast Moving Market Watchlists - Newser
Analyzing net buyer seller activity in Telomir Pharmaceuticals Inc.Rate Cut & Long-Term Capital Growth Strategies - Newser
Published on: 2025-09-12 05:33:48 - Newser
Earnings visualization tools for Telomir Pharmaceuticals Inc.2025 Support & Resistance & High Conviction Buy Zone Picks - Newser
How high can Telomir Pharmaceuticals Inc. stock goTrade Analysis Summary & Real-Time Price Movement Reports - Newser
Chart based exit strategy for Telomir Pharmaceuticals Inc.Portfolio Return Summary & Low Risk Growth Stock Ideas - Newser
Volume spikes in Telomir Pharmaceuticals Inc. stock – what they meanJuly 2025 Closing Moves & Accurate Technical Buy Alerts - Newser
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - The Florida Times-Union
Telomir’s drug candidate shows promise in reversing cancer gene silencing By Investing.com - Investing.com Nigeria
Telomir’s drug candidate shows promise in reversing cancer gene silencing - Investing.com
Telomir Pharmaceuticals IncTelomir-1 reverses Cdkn2a gene silencingSEC filing - MarketScreener
Key resistance and support levels for Telomir Pharmaceuticals Inc.2025 Pullback Review & Stock Portfolio Risk Management - Newser
Published on: 2025-09-09 08:39:23 - beatles.ru
Published on: 2025-09-09 02:00:19 - beatles.ru
statistical indicators supporting telomir pharmaceuticals inc.’s strengthQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Detecting support and resistance levels for Telomir Pharmaceuticals Inc.Short Setup & Real-Time Market Trend Scan - Newser
Telomir Pharmaceuticals Inc. Shows Early Signs of Technical StrengthMarket Sentiment Review & Weekly Momentum Stock Picks - beatles.ru
How to forecast Telomir Pharmaceuticals Inc. trends using time seriesPortfolio Update Summary & Proven Capital Preservation Methods - Newser
Using Python tools to backtest Telomir Pharmaceuticals Inc. strategiesJuly 2025 Analyst Calls & Expert Approved Momentum Ideas - Newser
Is Telomir Pharmaceuticals Inc. stock entering bullish territory2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
Is Telomir Pharmaceuticals Inc. still worth holding after the dipEntry Point & Verified Short-Term Plans - Newser
Will Telomir Pharmaceuticals Inc. stock recover after recent dropQuarterly Market Review & Technical Confirmation Alerts - Newser
Published on: 2025-09-08 04:15:57 - Newser
What the charts say about Telomir Pharmaceuticals Inc. todayGold Moves & Fast Exit Strategy with Risk Control - Newser
Telomir Pharmaceuticals Completes $2.9 Million Stock Sale - MSN
Automated trading signals detected on Telomir Pharmaceuticals Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
Is Telomir Pharmaceuticals Inc. a speculative investment2025 Key Lessons & Intraday High Probability Alerts - خودرو بانک
Returns Recap: Is Telomir Pharmaceuticals Inc. a cyclical or defensive stockQuarterly Earnings Report & AI Powered Trade Plan Recommendations - خودرو بانک
Telomir Posts Q2 2025 Earnings Loss; Market Reaction Points to Extended Downside Risk - AInvest
Telomir Pharmaceuticals Inc. stock volume spike explained2025 Market Overview & Technical Confirmation Alerts - Newser
What MACD and RSI say about Telomir Pharmaceuticals Inc.Earnings Growth Report & Consistent Profit Trading Strategies - Newser
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathway - IndyStar
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
3.65%
0.32%
大文字化:
|
ボリューム (24 時間):